Outlook Therapeutics to Present at the Virtual Investor Fireside Chat Series
Outlook Therapeutics, Inc. (Nasdaq: OTLK) announced that its President, CEO, and CFO, Lawrence A. Kenyon, will present at the Virtual Investor Fireside Chat Series on June 17, 2020, at 2:00 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Outlook Therapeutics, Inc. (Nasdaq: OTLK) announced that its President, CEO, and CFO, Lawrence A. Kenyon, will present at the Virtual Investor Fireside Chat Series on June 17, 2020, at 2:00 PM ET. The event aims to discuss the company’s progress in developing the first FDA-approved ophthalmic formulation of bevacizumab for retinal indications such as wet AMD and DME. A live Q&A session will follow, allowing attendees to interact directly with management. A webcast replay will be available two hours post-event for one year.
Details
News Market Reaction – OTLK
The recorded move for OTLK in the trading session of this news was -5.83%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MONMOUTH JUNCTION, N.J., June 09, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the Company), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Lawrence A. Kenyon, President, CEO and CFO of Outlook Therapeutics, will present at the Virtual Investor Fireside Chat Series on Wednesday, June 17, 2020 at 2:00 PM ET.
A live video webcast of the fireside chat will be available on the Events page of the Investors section of the Company’s website (outlooktherapeutics.com). Immediately following the fireside chat, management will participate in an interactive Q&A session with interested parties, allowing participants to type in questions and receive live responses. A webcast replay will be available two hours following the live presentation and will be accessible for one year.
To schedule a one-on-one call with management, please submit a request through the conference website vifiresidechat.com, or contact the conference at info@virtualinvestorco.com. For more information about the event, please visit vifiresidechat.com.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 / LYTENAVA™ (bevacizumab vikg), its investigational ophthalmic formulation of bevacizumab, is approved, Outlook Therapeutics expects to commercialize it as the first and only approved ophthalmic formulation of bevacizumab for use in treating approved retinal diseases in the United States, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway. For more information, please visit www.outlooktherapeutics.com.
CONTACTS:
Outlook Therapeutics:
Lawrence A. Kenyon
LawrenceKenyon@outlooktherapeutics.com
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
OTLK@jtcir.com
Media Inquiries:
Emmie Twombly
Media Relations Specialist
LaVoie Health Science
M: 857.389.6042
etwombly@lavoiehealthscience.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.